|
|
|
| Research progress in the application of metabolic glutamate receptor 5 positron emission tomography in neuropsychiatric diseases |
| ZHANG Linyue1 HUANG Qi2 HUA Fengchun1▲#br# |
1.Department of Nuclear Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China;
2.PET Center, Huashan Hospital Affiliated to Fudan University, Shanghai 200032, China
|
|
|
|
Abstract Metabolic glutamate receptors 5 (mGluR5) play an important role in neuropsychiatric diseases, positron emission tomography (PET) can noninvitatively assess mGluR5 changes in nervous system diseases at the in vivo molecular level. In order to further explore the changes and pathological mechanism of mGluR5 in neuropsychiatric diseases, this paper reviews the molecular mechanism of mGluR5 and the application of PET in Alzheimer’s disease, Parkinson disease, epilepsy, mental diseases, and sleep and arousal, etc., in order to provide guidance for the experimental research and clinical application of mGluR5 imaging.
|
|
|
|
|
|
[1] Mecca AP，Mcdonald JW，Michalak HR，et al. PET imaging of mGluR5 in Alzheimer’s disease [J]. Alzheimers Res Ther，2020，12（1）：15.
[2] Yeona K，Claire H，Ajay V，et al. 18F-FPEB PET/CT Shows mGluR5 Upregulation in Parkinson’s Disease [J]. J Neuroimaging，2019，29（1）：97-103.
[3] Dubois JM，Mathotaarachchi S，Rousset OG，et al. Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia [J]. Neuroimage Clin，2021，29（2）：102552.
[4] Murrough JW，Abdallah CG，Mathew SJ. Targeting glutamate signalling in depression：progress and prospects [J]. Nat Rev Drug Discov，2017，16（7）：472-486.
[5] Wang HY，Macdonald ML，Borgmann-Winter KE，et al. mGlu- R5 hypofunction is integral to glutamatergic dysregulation in schizophrenia [J]. Mol Psychiatry，2020，25（4）：750-760.
[6] Takamura Y，Kakuta H. In Vivo Receptor Visualization and Evaluation of Receptor Occupancy with Positron Emission Tomography [J]. J Med Chem，2021，64（9）：5226-5251.
[7] Ametamey SM，Treyer V，Streffer J，et al. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C- ABP688 [J]. J Nucl Med，2007，48（2）：247-252.
[8] Sephton SM，Herde AM，Mu L，et al. Preclinical evaluation and test-retest studies of [18F]PSS232，a novel radioligand for targeting metabotropic glutamate receptor 5 （mGlu5）[J]. Eur J Nucl Med Mol Imaging，2015，42（1）：128-137.
[9] Crestini A，Santilli F，Martellucci S，et al. Prions and Neurodegenerative Diseases：A Focus on Alzheimer’s Disease [J]. J Alzheimers Dis，2022，85（2）：503-518.
[10] Herde AM，Schibli R，Weber M，et al. Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients [J]. Eur J Nucl Med Mol Imaging，2019，46（2）：407- 420.
[11] Caraci F，Nicoletti F，Copani A. Metabotropic glutamate receptors：the potential for therapeutic applications in Alzhe- imer’s disease [J]. Curr Opin Pharmacol，2018，38：1-7.
[12] Hamilton A，Vasefi M，Vander Tuin C，et al. Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model [J]. Cell Rep，2016，15（9）：1859-1865.
[13] Haas LT，Salazar SV，Smith LM，et al. Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer’s Mouse Phenotypes [J]. Cell Rep，2017，20（1）：76-88.
[14] Kang Y，Henchcliffe C，Verma A，et al. 18F-FPEB PET/ CT Shows mGluR5 Upregulation in Parkinson’s Disease [J]. J Neuroimaging，2019，29（1）：97-103.
[15] Pourmirbabaei S，Dolatshahi M，Rahmani F. Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia [J]. Eur J Pharmacol，2019，855：149-159.
[16] Negida A，Ghaith Hs，Fala SY，et al. Mavoglurant（AFQ056）for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease：a meta-analysis [J]. Neurol Sci，2021，42（8）：3135-3143.
[17] Zhang YN，Fan JK，Gu L，et al. Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson’s disease [J]. J Neuroinflammation，2021，18（1）：23.
[18] Kovalenko AA，Zakharova MV，Schwarz AP，et al. Changes in Metabotropic Glutamate Receptor Gene Expression in Rat Brain in a Lithium-Pilocarpine Model of Temporal Lobe Epilepsy [J]. Int J Mol Sci，2022，23（5）：2752.
[19] Zimmermann M，Minuzzi L，Aliaga Aliaga A，et al. Reduced Metabotropic Glutamate Receptor Type 5 Availability in the Epileptogenic Hippocampus：An in vitro Study [J]. Front Neurol，2022（13）：888479.
[20] Esterlis I，Dellagioia N，Pietrzak RH，et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response：an [11C]ABP688 and PET imaging study in depression [J]. Mol Psychiatry，2018，23（4）：824-832.
[21] Lam J，Dubois JM，Rowley J，et al. In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy [J]. Ann neurol，2019，85（2）：218-228.
[22] Dogra S，Conn PJ. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders [J]. Neuropharmacology，2021，196：108687.
[23] Holmes SE，Girgenti MJ，Davis MT，et al. Altered metabotr- opic glutamate receptor 5 markers in PTSD：In vivo and postmortem evidence [J]. Proc Natl Acad Sci U S A，2017， 114（31）： 8390-8395.
[24] Davis MT，Hillmer A，Holmes SE，et al. In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal idea- tion [J]. Proc Natl Acad Sci U S A，2019，116（23）：11490- 11495.
[25] Kim JH，Joo YH，Son YD，et al. Differences in mGluR5 Availability Depending on the Level of Social Avoidance in Drug-Na?觙ve Young Patients with Major Depressive Disorder [J]. Neuropsychiatr Dis Treat，2022，18：2041-2053.
[26] Holmes SE，Asch RH，Davis MT，et al. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder [J]. Biol Psychiatry，2022，93（22）： 1099-1107.
[27] Silverman JL，Smith DG，Rizzo SJ，et al. Negative Allosteric Modulation of the mGluR5 Receptor Reduces Repetitive Behaviors and Rescues Social Deficits in Mouse Models of Autism [J]. Sci Transl Med，2012，4（131）：131ra51.
[28] Kordestani-Moghadam P，Nasehi M，Khodagholi F，et al. The fluctuations of metabotropic glutamate receptor subtype 5 （mGluR5） in the amygdala in fear conditioning model of male Wistar rats following sleep deprivation，reverse circadian and napping [J]. Brain Res，2020，1734：146739.
[29] Weigend S，Holst SC，Treyer V，et al. Dynamic changes in cerebral and peripheral markers of glutamatergic signaling across the human sleep-wake cycle [J]. Sleep，2019，42（11）：zsz161.
[30] Aguilar DD，Strecker RE，Basheer R，et al. Alterations in sleep，sleep spindle，and EEG power in mGluR5 knockout mice [J]. J Neurophysiol，2020，123（1）：22-33.
[31] Mecca AP，Rogers K，Jacobs Z，et al. Effect of Age on Brain Metabotropic Glutamate Receptor Subtype 5 Measured with [18F]FPEB PET [J]. NeuroImage，2021，238：118-217.
[32] de Laat B，Weerasekera A，Leurquin-Sterk G，et al. Effects of alcohol exposure on the glutamatergic system：a combined longitudinal 18F-FPEB and 1H-MRS study in rats [J]. Addict Biol，2019，24（4）：696-706.
[33] Ceccarini J，Leurquin-Sterk G，Crunelle CL，et al. Recovery of decreased metabotropic glutamate receptor 5 availability in abstinent alcohol-dependent patients [J]. J Nucl Med，2020，61（2）：256-262.
[34] Brambilla CR，Veselinovi■ T，Rajkumar R，et al. mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia [J]. Hum Brain Mapp，2020，41（10）：2762- 2781.
[35] Herde AM，Mihov Y，Krmer SD，et al. Chronic Nicotine Exposure Alters Metabotropic Glutamate Receptor 5：Longitudinal PET Study and Behavioural Assessment in Rats [J]. Neurotox Res，2019，36（4）：806-816.
[36] Smart K，Cox SML，Nagano-Saito A，et al. Test-retest variability of [11C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans [J]. Synapse，2018， 72（9）：e22041. |
|
|
|
